All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J., January 30 ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Merck & Co. has ended another late-stage study of its Winrevair treatment for pulmonary arterial hypertension, or PAH, early due to strong evidence of the drug's benefit. Merck on Thursday said ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial hypertension functional class II or III at intermediate or ...

Could Zoltux's Instant Solar Kit Be the Answer to Hassle-Free Solar Power? My Favorite Ina Garten Recipe Is So Lazy, It's Brilliant Against the odds, Prince Harry has won a landmark victory ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...